Sentara enrolls first Virginia patient in national clinical trial focused on treating chronic leg pain
Sentara Healthcare has enrolled the very first patient in Virginia into the INFINITE-US clinical trial. This clinical trial will study the safety and efficacy of using an innovative, less invasive procedure to treat patients suffering from chronic venous insufficiency (CVI).
Chronic venous insufficiency (CVI) affects roughly 20% of the adult population and occurs when your leg veins don’t allow blood flow back up to your heart. This can cause blood to collect in your legs and result in chronic pain for patients. The INFINITE-US clinical trial uses what’s called a BlueLeaf® Endovenous Valve Formation System, the first non-surgical potential treatment for CVI. The device is intended to form new tissue leaflets within the vein walls without the use of a permanent vascular implant.
The INFINITE-US trial is currently enrolling more patients who suffer from CVI. This trial is being conducted at just five select locations in the United States, with Sentara Healthcare being the only site located in Virginia. Other states include New York, Pennsylvania, Connecticut, and North Carolina.
Sentara Vascular Surgeon Dr. David Dexter is the principal investigator of this study. Dr. Dexter is certified by the American Board of Surgery, is uniquely trained in the diagnosis and management of venous disease, and specializes in endovascular surgery. Sentara Vascular Specialists, part of Sentara Medical Group, has offices and treatment facilities located across Hampton Roads.
The Sentara Health Research Center is also supporting this clinical trial. The Sentara Health Research Center formed in 2020 and provides greater structure, administrative oversight, and regulatory support for research conducted across Sentara Healthcare. Our research is dedicated to improving patient lives and finding solutions to health inequities within our communities.
To learn more about participating in the INFINITE-US clinical trial, or to search other clinical trials Sentara is involved in, visit this website.
By: Kelly Kennedy